Rasio rega marang prakiraan pendapatan ImmunoPrecise Antibodies Ltd. (IPA)
ImmunoPrecise Antibodies (IPA) develops therapeutic antibodies using AI, bypassing traditional laboratories through digital screening. The forward P/S multiple reflects the market consensus trend, and 5.40 is currently becoming the new value for this metric. A strong team of engineers in Europe and Canada ensures research quality, while the deep integration of AI platforms into B2B protocols guarantees high customer loyalty.
Rincian metrik lan analitis perusahaan immunoprecise.com (IPA)
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- indikator nilai buku ekuitas:
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal ImmunoPrecise Antibodies|IPA - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas ImmunoPrecise Antibodies Ltd.|IPA - Utang agregat perusahaan|Utang marang nilai buku ImmunoPrecise Antibodies Ltd.|IPA - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan ImmunoPrecise Antibodies|Rasio cepet immunoprecise.com
- rincian asil keuangan lan kelipatan valuasi:
IPA - Bathi resik perusahaan|Bathi sing dikarepake ImmunoPrecise Antibodies|IPA - Kapitalisasi marang bathi|Pangali Forward P/E ImmunoPrecise Antibodies Ltd.|IPA - Rasio P/E diaturake wutah|Pangali EV/EBITDA ImmunoPrecise Antibodies Ltd.|IPA - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) ImmunoPrecise Antibodies|IPA - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan immunoprecise.com|IPA - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep ImmunoPrecise Antibodies
- rincian pendapatan lan dodolan:
Pambiji fundamental perusahaan:ImmunoPrecise (IPA)
High R&D expenditures coupled with a deficit in operating cash flow at ImmunoPrecise Antibodies (IPA) make the company's expected P/S chart a key tool for assessing market expectations. The current value of 5.40 reflects the ratio of market capitalization to projected revenue, allowing for a determination of the degree of business undervaluation or the risk of overpaying for future sales amid a cash gap.
Perusahaan pesaing
Multiplikator Forward P/S TEM (Tempus AI, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Qiagen NV (QGEN)|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Repligen Inc. RGEN|RNA: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep crisprtx.com (CRSP)|Multiplikator forward rega marang pendapatan WGS|RARE: Rega forward marang dodolan|Multiplikator Forward P/S BEAM|Multiplikator Forward P/S Sarepta Corp (SRPT)|Rasio rega marang prakiraan pendapatan Twist Bioscience TWST|TXG: Kapitalisasi marang prakiraan pendapatan|NTLA: Multiplikator forward rega marang pendapatan|Stoke Therapeutics Inc - Rasio rega marang pendapatan sing dikarepake|BLFS: Multiplikator Forward P/S|WVE - Rasio kapitalisasi marang dodolan sing dikarepake|MAZE (Maze Therapeutics Inc) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan SION|Rasio rega marang prakiraan pendapatan Prime Medicine (PRME)|TSHA - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S QURE (uniQure Corp)|MGTX: Kapitalisasi marang prakiraan pendapatan|REGENXBIO Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake solidbio.com SLDB|OCGN: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pacific Biosciences of California, Inc. (PACB)|Rasio rega marang prakiraan pendapatan Benitec|Design Corp (DSGN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S RCKT|Rasio kapitalisasi marang dodolan sing dikarepake 4dmoleculartherapeutics.com|Rasio rega marang prakiraan pendapatan Lexeo Therapeutics, Inc. LXEO|KRRO (Korro Bio Inc.) - Rega mangsa ngarep marang pendapatan|Editas - Multiplikator Forward P/S|SLN - Multiplikator Forward P/S|PRQR: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan CDXS|Rasio rega marang prakiraan pendapatan Sangamo Therapeutics, Inc.|Kapitalisasi marang prakiraan pendapatan NAUT (Nautilus Biotechnology Inc)|Multiplikator Forward P/S MGX|Multiplikator Forward P/S Precision BioSciences Inc. (DTIL)|Multiplikator Forward P/S GBIO (Generation Bio)|Rasio kapitalisasi marang dodolan sing dikarepake boundlessbio.com (BOLD)|XCUR - Rasio rega marang prakiraan pendapatan|Imunon, Inc. (IMNN) - Multiplikator forward rega marang pendapatan|phiopharma.com (PHIO) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Mustang Bio|Multiplikator forward rega marang pendapatan RNAZ|Multiplikator Forward P/S Bionano|Rasio rega marang prakiraan pendapatan Applied DNA Sciences, Inc. (APDN)|bluebird bio Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega OMGA|Singular Genomics Corp (OMIC) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RGLS - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan SYRS|Telesis Bio (TBIO) - Rasio rega marang prakiraan pendapatan|TRACON Pharmaceuticals Inc. - Rega forward marang dodolan|UBX (Unity Bio) - Multiplikator Forward P/S
